Market Segmentation:
- By Treatment Type
- Drugs
- Devices
- Others (Dialysis, Supportive Care)
- By Drug Type
- Diuretics
- Vasodilators
- Antibiotics
- Others (Anti-inflammatory, Antioxidants)
- By Route of Administration
- Oral
- Intravenous
- Others (Subcutaneous, Intramuscular)
- By End-User
- Hospitals
- Ambulatory Surgical Centers
- Dialysis Centers
- Others (Home Healthcare, Clinics)
- By Cause
- Ischemic Injury
- Nephrotoxic Injury
- Sepsis 4
- Others (Obstructive, Glomerular Disease)
- By Stage
- Risk
- Injury
- Failure
- Loss
- End-Stage Renal Disease (ESRD)
- By Severity
- Mild
- Moderate
- Severe
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the Acute Kidney Injury (AKI) industry is US$ 920 million.
The key factors contributing significantly to the growth of the Acute Kidney Injury (AKI) market include the rising prevalence of chronic diseases such as diabetes, hypertension, and cardiovascular diseases, increasing healthcare expenditure, advancements in diagnostic techniques, and technological advancements in treatment modalities.
The key factors hampering the growth of the Acute Kidney Injury (AKI) Market include the high cost of treatment, stringent regulatory requirements, lack of awareness and early detection, and limited treatment options.
The leading component segment in the Acute Kidney Injury (AKI) Market is the Drugs segment, which includes various therapeutic agents used for the treatment of AKI.
The major players operating in the Acute Kidney Injury (AKI) Market include Baxter International Inc., Angion Biomedica Corp., Quipu Life, AM-Pharma, Asahi Kasei Medical Co., Ltd., Novartis AG, Pfizer Inc., Sanofi, GlaxoSmithKline plc, and AstraZeneca.
The Acute Kidney Injury (AKI) Market is expected to reach US$ 1,929.5 billion by 2031, growing at a CAGR of 9.7% during the forecast period.
The key drivers of the Acute Kidney Injury (AKI) Market include the rising prevalence of chronic diseases, increasing healthcare expenditure, advancements in diagnostic techniques, and technological advancements in treatment modalities.